Reclast (Zoledronic Acid) for Adolescents (Ages 12 to 17): Transitioning to Adult Care

Why Transition Planning Matters for Adolescents on Zoledronic Acid

Transitioning from pediatric to adult bone-health care is not simply a change of address on a referral form. For adolescents who have been receiving IV zoledronic acid, the stakes are real: bisphosphonates bind avidly to hydroxyapatite and can persist in bone for a decade or more after the last dose. Compston et al. (2017) note that residual skeletal drug concentrations continue to suppress osteoclast activity well beyond the infusion window, which means the transition period influences long-term fracture risk even if no new doses are given.

Adolescence is also the phase of peak bone mass accrual. Roughly 90% of adult peak bone mass is deposited by age 18, according to data from the National Institutes of Health. Weaver et al. (2016) reported that optimizing calcium and vitamin D through adolescence is independently associated with peak bone mass outcomes in young adults. Any disruption to monitoring or supplementation during the handover window can erode gains made during years of IV therapy.

What "Transition" Actually Means Clinically

Transition is not a single appointment. It is a 12-to-24-month process that ideally begins at age 16 to 17, while the adolescent still has access to the pediatric team. The goal is to build a shared record that the adult endocrinologist or rheumatologist can act on immediately.

The pediatric provider should prepare a transition summary that includes: the primary diagnosis driving bisphosphonate use (osteogenesis imperfecta, glucocorticoid-induced osteoporosis, idiopathic juvenile osteoporosis, or another cause), a complete infusion log with dates and cumulative dose, all prior DXA reports with Z-scores, fracture history, and the most recent calcium and vitamin D levels. Without this document, the adult provider must reconstruct years of history from scratch, creating the exact gaps that lead to under- or over-treatment.

The Skeletal Maturity Checkpoint

Zoledronic acid dosing in pediatric practice is weight-based and off-label. The adult Reclast label specifies 5 mg IV once per year for postmenopausal osteoporosis and Paget disease, but the FDA has not approved zoledronic acid for pediatric osteoporosis. The FDA prescribing information for Reclast explicitly states that safety and efficacy in pediatric patients have not been established for the osteoporosis indication.

Growth-plate closure, confirmed radiographically, is the standard clinical trigger for switching from weight-based pediatric dosing to the adult 5 mg annual regimen. Most clinicians and the Endocrine Society's 2017 pediatric bone guidelines recommend confirming Tanner stage V and skeletal age before making that shift.

Zoledronic Acid Dosing: Pediatric vs. Adult Regimens

Dosing is one of the most consequential details the transition summary must document. Pediatric providers typically use 0.025 to 0.05 mg/kg IV per infusion cycle, administered every 6 or 12 months depending on disease severity. Glorieux et al. (2004) established early evidence for IV pamidronate in osteogenesis imperfecta, and subsequent cohort data have guided zoledronic acid dosing in OI patients, with most centers settling around 0.05 mg/kg per infusion capped at 4 mg per dose.

Moving to the Adult 5 mg Annual Dose

Once skeletal maturity is confirmed, the adult 5 mg annual infusion becomes appropriate for patients whose indication persists into adulthood (for example, those with continued glucocorticoid exposure or OI type I). Reid et al. (2009, NEJM) demonstrated that a single 5 mg infusion in postmenopausal women produced a 70% reduction in vertebral fracture risk over 3 years in the HORIZON Key Fracture Trial (N=7,736), establishing the efficacy benchmark against which the adult regimen is judged.

The timing of the first adult-dosed infusion should account for the last pediatric infusion date. Stacking doses by transitioning too quickly risks over-suppression of bone turnover. A gap of at least 12 months from the last pediatric infusion is the standard approach before initiating the adult 5 mg dose, though this may be shortened in patients with persistently high fracture risk.

Infusion-Day Hydration and Premedication

Renal function is a non-negotiable checkpoint before every zoledronic acid infusion. The Reclast label contraindicates use when creatinine clearance is below 35 mL/min. Adolescents transitioning to adult nephrology or primary care may not have a recent creatinine on file. The receiving adult provider must verify renal function within 30 days of each infusion.

Pre-hydration with at least 500 mL of fluid before the infusion reduces the risk of acute-phase reaction and protects renal tubules. Acetaminophen 650 to 1,000 mg taken one hour before infusion reduces the flu-like symptoms (fever, myalgia, arthralgia) that affect approximately 32% of first-time recipients, based on data from Black et al. (2007) in the HORIZON trial.

Monitoring Labs and DXA at the Time of Transfer

A clean lab handoff protects the patient from the most common transition failure: running out of vitamin D or discovering hypocalcemia after the adult provider has already scheduled the infusion.

Required Labs Before Transfer

The minimum lab panel that should be completed within 60 days of the final pediatric visit includes:

• Serum 25-OH vitamin D (target at least 20 ng/mL, preferably 30 to 50 ng/mL)
• Serum calcium and albumin (to calculate corrected calcium)
• Creatinine and estimated GFR
• Serum phosphate
• Alkaline phosphatase (as a bone turnover marker surrogate)

Holick et al. (2011) in the Endocrine Society's vitamin D guideline recommended that patients on antiresorptive therapy maintain a 25-OH vitamin D level above 30 ng/mL to prevent bisphosphonate-related hypocalcemia, which is the most common acute adverse event following infusion.

DXA Timing and Z-Score vs. T-Score

In adolescents and young adults under age 20, DXA results should be reported as Z-scores (comparison to age-matched peers), not T-scores. T-scores are only valid for postmenopausal women and men over 50 by International Society for Clinical Densitometry (ISCD) standards. A DXA completed within 12 months of the transition visit is sufficient to hand off. If the most recent DXA is more than 24 months old, repeating it before transfer is advisable.

Schousboe et al. (2013) in the Journal of Clinical Densitometry outlined the ISCD guidelines for DXA reporting in children and adolescents, specifying that a Z-score of -2.0 or below, combined with a clinically significant fracture history, defines low bone density for chronological age. The adult provider needs to know whether the patient arrived at the transition with a Z-score of -1.5 or -3.0, because that baseline determines how aggressively the adult regimen should proceed.

When to Resume or Continue DXA in Adult Care

DXA every 1 to 2 years is standard for patients continuing antiresorptive therapy in adulthood. Patients who discontinue zoledronic acid at transition (for example, those who completed OI treatment with stable fracture rates) may be monitored with DXA every 2 to 3 years, depending on fracture risk. The adult provider should set a formal monitoring schedule at the first visit and document it in the shared care plan.

Safety Signals That Must Transfer with the Patient

Several long-term safety concerns associated with bisphosphonate therapy require explicit documentation at transition. These are not theoretical. Two deserve special attention in the adolescent transitioning to adult care.

Osteonecrosis of the Jaw

Osteonecrosis of the jaw (ONJ) is rare with annual low-dose Reclast but is more frequently reported with high-dose or high-frequency IV bisphosphonate regimens used in oncology. Khan et al. (2015) estimated the ONJ incidence at 0.01 to 0.04% in patients on osteoporosis-dose IV bisphosphonates, compared to 1 to 15% in oncology doses. Adolescents are in peak orthodontic and dental surgical years. The transition summary must include a dental clearance date and note any planned oral surgical procedures.

The adult provider should confirm dental clearance before scheduling the first adult-dosed infusion. Elective extractions or implant placements should be completed and healed (minimum 3 months post-procedure) before resuming therapy.

Atypical Femoral Fractures

Atypical subtrochanteric or diaphyseal femoral fractures are a recognized complication of long-duration bisphosphonate therapy. Shane et al. (2014) in the ASBMR task force report identified a relative risk increase of approximately 100-fold for atypical femoral fractures in patients on bisphosphonates for more than 5 years, though absolute risk remains low (3.2 to 50 per 100,000 person-years). Adolescents who began bisphosphonate therapy at age 10 to 12 for OI or glucocorticoid-induced osteoporosis may be approaching or past the 5-year cumulative exposure mark by the time they transition.

The transition summary must document total cumulative years of bisphosphonate exposure. The adult provider should ask the patient about any new thigh, hip, or groin pain at each visit. Bilateral femoral X-rays or MRI should be ordered promptly if atypical fracture is suspected.

The Transition Summary Document: A Practical Framework

Every adolescent leaving pediatric bone care should carry a transition summary. Below is the minimum content standard for a complete document.

Section 1: Diagnosis and Clinical History

Include the primary diagnosis with ICD-10 code, the date of diagnosis, and the clinical rationale for initiating bisphosphonate therapy. Document fracture history by site, date, and mechanism. Note whether the patient has any co-existing conditions that affect bone metabolism: celiac disease, inflammatory bowel disease, chronic steroid use, eating disorders, or hypophosphatasia.

Section 2: Treatment Log

List every bisphosphonate infusion with date, drug name, dose in mg/kg and absolute mg, infusion duration, and any adverse events. If the patient received pamidronate before transitioning to zoledronic acid (a common sequence in OI care), that history belongs here too. Dwan et al. (2016) in the Cochrane review of bisphosphonates for OI noted that cumulative drug exposure is a key variable in assessing long-term bone turnover suppression.

Section 3: Lab Trend Data

Provide a table of 25-OH vitamin D, calcium, creatinine, and alkaline phosphatase values over the past 3 years. Trends matter more than single values. A vitamin D that has been consistently 18 to 22 ng/mL despite supplementation signals a need for dose escalation, while a creatinine creeping up over 2 years flags renal safety concerns that the adult nephrologist must evaluate before the next infusion.

Section 4: Imaging Summary

List all DXA reports with date, machine, software version, lumbar spine Z-score, total hip Z-score, and any site-specific notes. List all fracture X-rays. If the patient has had femoral geometry measured (hip structural analysis), include that data.

Section 5: Current Medications and Supplements

Document current calcium supplementation dose (mg/day), vitamin D supplement dose (IU/day), and any other bone-active agents. The Endocrine Society recommends 1,300 mg/day of calcium for adolescents aged 14 to 18 and 1,000 mg/day for adults aged 19 to 50, per the NIH Office of Dietary Supplements calcium fact sheet. Discrepancies between recommended and actual intake should be flagged.

Reproductive Health Considerations at Transition

This section is clinically critical for adolescent females and is frequently omitted from transition summaries.

Zoledronic acid is classified as FDA Pregnancy Category D (now described under the 2015 PLLR framework as having demonstrated fetal risk in animal studies and limited human data). Bisphosphonates cross the placenta and incorporate into fetal bone. Djokanovic et al. (2008) reviewed outcomes in 51 pregnancies with bisphosphonate exposure and found hypocalcemia in neonates born to mothers who received IV bisphosphonates.

Contraception Counseling

Female adolescents transitioning to adult care should receive explicit contraception counseling at the final pediatric visit and the first adult visit. The long skeletal half-life of zoledronic acid means that drug may still be releasing from bone during a pregnancy that occurs years after the last infusion. There is no established safe interval between the last bisphosphonate dose and conception, though some expert opinion suggests waiting at least 12 months after the last infusion before attempting pregnancy.

The American College of Obstetricians and Gynecologists has addressed bisphosphonate use in women of reproductive age, recommending individualized counseling about risks versus benefits for those who require continued therapy.

Male Adolescents

Male patients are not exempt from reproductive counseling. Animal data suggest bisphosphonate accumulation in testes, though human fertility data are sparse. The adult provider should document that this conversation occurred.

The Adult Provider's Checklist at the First Visit

The receiving adult endocrinologist, rheumatologist, or primary care physician should complete the following at the first transition visit.

First, confirm receipt of the full transition summary and identify any gaps. Second, review the last DXA and determine whether to order a new baseline scan. Third, verify lab values within 60 days: calcium, vitamin D, creatinine, phosphate. Fourth, confirm dental clearance and document the date. Fifth, assess cumulative bisphosphonate years and screen for atypical femur symptoms. Sixth, perform or document reproductive health counseling. Seventh, set the next infusion date if continued therapy is indicated, or document the rationale for a drug holiday.

A bisphosphonate drug holiday is worth considering for patients who have achieved a stable Z-score and have low ongoing fracture risk. Black et al. (2006) in the FLEX trial (N=1,099) found that women who discontinued alendronate after 5 years maintained fracture protection for an additional 5 years due to residual skeletal drug effect, though this data comes from a postmenopausal population and should be extrapolated to young adults with caution.

What Adolescents and Their Families Should Know

Patients and caregivers often arrive at the adult system without a clear understanding of why IV therapy continues, how long it will last, or what symptoms should prompt a call to the new provider. Three questions come up consistently in clinical practice.

"Will I be on this forever?" Not necessarily. Many patients with OI type I or resolved glucocorticoid exposure can take a drug holiday after reaching a stable DXA plateau. The adult provider will reassess this at each annual visit.

"What if I miss an infusion?" Zoledronic acid's long skeletal half-life provides a degree of protection. A delay of 2 to 3 months is unlikely to result in rapid bone loss in a patient who has been on therapy for several years. Missing an infusion is not an emergency, but it should be rescheduled promptly. Bone et al. (2017) demonstrated sustained anti-fracture efficacy for up to 6 years of annual zoledronic acid in the HORIZON extension trial.

"Are there side effects I should watch for?" The acute-phase reaction after the first adult-dosed infusion (fever, flu-like symptoms, bone pain) is the most common short-term concern. It typically resolves within 3 days and can be managed with acetaminophen and hydration. New thigh or hip pain at any time should be reported to the provider before the next infusion.